Pharmacokinetic Study of TV-44749 Extended-release in Participants with Schizophrenia

Study Title
A Multi-center, Open-label, Randomized, Parallel-group Trial to Characterize the pharmacokinetics of three SC Olanzapine Extended-Release Formulations with Different Release Rates Following Single Administration in Participants with Schizophrenia or Schizoaffective Disorder
Teva Identifier
TV44749-NPC-10205
ClinicalTrials.gov Identifier
NCT06319170
Study Status
Recruiting
Trial Condition(s)
Schizophrenia, Schizoaffective Disorder
Interventions
Drug: TV-44749

Study Description

The primary objective of the study is to characterize the pharmacokinetics of 3 formulations of olanzapine.
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years to 64 Years
Trial Duration
March 28, 2024 - December 11, 2024
Phase
Phase 1

Study Type

Interventional